文献速递膀胱癌与上尿路尿路上皮癌

卡介苗短缺期间非肌层浸润性膀胱癌的治疗模式

Treatment Patterns for Non-muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Shortage.
PubMed 文献 · Urology · 2025-07-23

基于SEER-Medicare数据回顾性分析2005-2014年诊断的非肌层浸润性膀胱癌患者,评估卡介苗短缺期间治疗模式变化。共纳入24410例患者,其中16559例首次治疗接受卡介苗。2012年首次短缺后卡介苗使用概率未变,2014年第二次短缺后概率略降0.072(95%CI -0.111至-0.333),随后保持稳定。

要点

  • 2012年首次BCG短缺后,NMIBC患者接受BCG治疗的概率未发生变化。
  • 2014年第二次BCG短缺后,BCG治疗概率下降0.072(95%CI -0.111至-0.333)。
  • BCG短缺对肿瘤学结局和疾病进展的影响需进一步研究。

核心结论

  • 2012年首次BCG短缺后NMIBC的BCG及其他膀胱内治疗使用未变,2014年第二次短缺后BCG治疗概率略降。

研究设计与样本

  • 利用SEER-Medicare数据的回顾性研究,纳入2005-2014年诊断的NMIBC患者,随访索赔至2015年。
  • 采用多项广义logistic回归(聚类稳健标准误)预测季度病例组合调整后的治疗概率,并调整年龄、性别、种族、婚姻状况、教育、人口、城市居住、收入、地区、合并症和肿瘤分级。
  • 使用中断时间序列分析(交错实施)检查2012年6月至2014年8月BCG短缺前后的趋势。

主要发现

  • 共识别24410例患者,其中16559例在研究期间首次治疗接受BCG。
  • 2012年首次已知BCG短缺后,病例组合调整的BCG治疗概率不变。
  • 2014年第二次已知BCG短缺后,病例组合调整的BCG治疗概率立即下降0.072(95%CI [-0.111, -0.333]),随后持续趋势保持恒定。

临床怎么用

  • 临床医生在BCG短缺期间应关注治疗模式变化,2014年后BCG使用概率略降,需评估替代膀胱内治疗。
  • 需进一步研究BCG短缺对肿瘤学结局和疾病进展的影响。

局限性

  • 研究为回顾性设计,基于SEER-Medicare数据,可能存在未测量混杂。
  • 随访索赔截至2015年,长期结局未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the trends in the use of Bacillus Calmette-Guerin (BCG) and other intravesical agents in the management of risk non-muscle invasive bladder cancer (NMIBC) during times of BCG shortage. METHODS: Using Surveillance, Epidemiology and End Results (SEER)-Medicare data, we conducted a retrospective study of patients diagnosed with NMIBC between 2005 and 2014, with follow-up claims through 2015. We used multinomial generalized logistic regression with clustered robust standard errors to predict quarterly, case-mix adjusted probabilities of treatment. We adjusted for age, sex, race, marital status, education, population, urban residence, income, region, comorbidities, and tumor grade. We used an interrupted time series with staggered implementation for these case-mix adjusted probabilities to examine trends before and during BCG shortages between June 2012 and August 2014. RESULTS: We identified 24,410 patients, 16,559 of whom received BCG as their first treatment during the study period. Following the first known BCG shortage in 2012, the case-mix adjusted probability of BCG treatment was unchanged. Immediately following the second known BCG shortage in 2014, the case-mix adjusted probability of BCG decreased by 0.072 (95% Confidence Interval [-0.111, -0.333]) with a sustained trend that remained constant. CONCLUSION: The use of BCG and other intravesical agents for the management of NMIBC remained unchanged after the first known BCG shortage in 2012. The probability of BCG treatment decreased slightly after the second shortage in 2014. Further investigation is warranted to assess the impact of this on oncologic outcomes and disease progression.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Obiora D, Yu M, Sharbaugh D, et al. Treatment Patterns for Non-muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Shortage. Urology. 2025. PMID: 40712798. doi:10.1016/j.urology.2025.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。